Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 3Other hematologic neoplasm 2Gynecologic 2Thoracic 1Other 1Myeloid 1Dermatologic 1CNS 1

Conditions

Osteochondroma 1Non-alcoholic Fatty Liver Disease 1Nevus, Epithelioid and Spindle Cell 1Malnutrition 1Lung Neoplasms 1Hematologic Neoplasms 1Giant Cell Tumors 1Gastrointestinal Neoplasms 1Fibrosis 1Esophageal Squamous Cell Carcinoma 1Endometrial Hyperplasia 1Carcinoma, Lobular 1Carcinoma in Situ 1Barrett Esophagus 1

Interventions

Oxaliplatin 1435Fluorouracil 1316Capecitabine 1112Gemcitabine 1054Leucovorin 935Bevacizumab 845Irinotecan 827Cisplatin 673Radiotherapy 559Cetuximab 481pembrolizumab 435Paclitaxel 400Drug Therapy 358Nivolumab 349130-nm albumin-bound paclitaxel 326Docetaxel 289Sorafenib 288S 1 (combination) 278Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 256lenvatinib 222sintilimab 218tislelizumab 213durvalumab 211regorafenib 208Radiosurgery 204Magnetic Resonance Spectroscopy 203apatinib 202Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sampling Studies × Gastrointestinal × Clear all
NCT02573974 2025-12-22

METERMUCADIG

University Hospital, Tours

Phase NA Completed
51 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Malnutrition

NCT05463796 2025-08-07

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

Dana-Farber Cancer Institute

Recruiting
5,000 enrolled
GastrointestinalGynecologicOther hematologic neoplasmThoracic

Barrett Esophagus, Carcinoma in Situ, Endometrial Hyperplasia, Fibrosis, Giant Cell Tumors, Lung Neoplasms, Osteochondroma, Carcinoma, Lobular, Nevus, Epithelioid and Spindle Cell, Hematologic Neoplasms, Non-alcoholic Fatty Liver Disease

NCT04666090 2025-05-15

Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Active not recruiting
42 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡